| Company
| InsiderPie Expert Score
| P/E ratio
| Gross margin
| EBIT margin
| ROA
| Net income per employee
|
| Mersana Therapeutics, Inc.
|
53
/ 100
| -0.68
| 99.1%
| -203.1%
| -111.8%
| -€585.14K
|
| Madrigal Pharmaceuticals, Inc.
|
53
/ 100
| -23
| 95.3%
| -41.5%
| -21.2%
| -€466.35K
|
| Iovance Biotherapeutics, Inc.
|
50
/ 100
| -1.9
| 38.8%
| -166.3%
| -43.9%
| -€404.11K
|
| ACADIA Pharmaceuticals Inc.
|
54
/ 100
| 14
| 91.9%
| 23.0%
| 19.6%
| €340.62K
|
| Poseida Therapeutics, Inc.
|
52
/ 100
| -16
| 95.4%
| -41.4%
| -20.2%
| -€144.54K
|
| Bellicum Pharmaceuticals, Inc.
|
50
/ 100
| -0.036
| 100.0%
| -1,528.7%
| -318.1%
| -€1.43M
|
| Codiak BioSciences, Inc.
|
50
/ 100
| 0
| 100.0%
| -158.8%
| -21.8%
| -€244.10K
|
| MannKind Corporation
|
51
/ 100
| 40
| 75.2%
| 23.2%
| 5.9%
| €61.78K
|
| Veru Inc.
|
53
/ 100
| -3
| 39.9%
| -512.6%
| -119.7%
| -€132.66K
|
| BridgeBio Pharma, Inc.
|
60
/ 100
| -9.6
| 96.2%
| -172.2%
| -79.9%
| -€936.36K
|
| Medigene AG
|
50
/ 100
| -0.12
| 78.4%
| -242.9%
| -57.8%
| -€191.39K
|
| Molecular Templates, Inc.
|
50
/ 100
| -0.000042
| 63.3%
| -33.7%
| -58.5%
| -€214.64K
|
| Sino Biopharmaceutical Limited
|
50
/ 100
| 168
| 81.8%
| 21.1%
| 5.2%
| €19.42K
|
| Futura Medical plc
|
50
/ 100
| -0.054
| 66.2%
| -34.3%
| -38.4%
| -€429.26K
|
| Aadi Bioscience, Inc.
|
46
/ 100
| -6.1
| 89.2%
| -754.0%
| -9.4%
| -€250.96K
|
| Autolus Therapeutics plc
|
49
/ 100
| -2.7
| -65.3%
| -535.8%
| -34.0%
| -€295.91K
|
| Arrowhead Pharmaceuticals, Inc.
|
51
/ 100
| -16
| 35.4%
| -13.2%
| -10.9%
| -€211.16K
|
| Protalix BioTherapeutics, Inc.
|
51
/ 100
| 23
| 57.5%
| 10.3%
| 6.6%
| €21.57K
|
| Atara Biotherapeutics, Inc.
|
49
/ 100
| 2.6
| 81.6%
| 17.3%
| 77.6%
| €130.26K
|
| hVIVO plc
|
50
/ 100
| 0.03
| 60.9%
| 18.2%
| 30.1%
| €102.44K
|
| MorphoSys AG
|
48
/ 100
| -5.4
| 79.8%
| -219.7%
| -25.1%
| -€991.95K
|
| Axsome Therapeutics, Inc.
|
45
/ 100
| -23
| 91.9%
| -37.8%
| -34.3%
| -€274.54K
|
| MacroGenics, Inc.
|
49
/ 100
| -1.4
| 73.7%
| -90.1%
| -28.0%
| -€189.52K
|
| Incyte Corporation
|
65
/ 100
| 11
| 92.9%
| 30.8%
| 18.8%
| €386.80K
|
| ORIC Pharmaceuticals, Inc.
|
53
/ 100
| -5
| 41.8%
| -27,771.7%
| -31.4%
| -€944.28K
|
| Regeneron Pharmaceuticals, Inc.
|
60
/ 100
| 12
| 84.4%
| 26.0%
| 11.4%
| €257.21K
|
| Applied Genetic Technologies Corporation
|
52
/ 100
| 0
| 100.0%
| -15,888.3%
| -61.5%
| -€294.33K
|
| Innoviva, Inc.
|
55
/ 100
| 11
| 84.8%
| -3.2%
| 8.9%
| €853.95K
|
| Seres Therapeutics, Inc.
|
50
/ 100
| 13
| -4,005.7%
| -29,467.0%
| 3.8%
| €44.60K
|
| Vericel Corporation
|
49
/ 100
| 171
| 73.8%
| 2.7%
| 2.9%
| €31.21K
|
| OptiBiotix Health Plc
|
50
/ 100
| -0.042
| 34.1%
| -269.7%
| -34.7%
| -€365.74K
|
| Sutro Biopharma, Inc.
|
48
/ 100
| -0.32
| 96.4%
| -175.7%
| -103.4%
| -€686.28K
|
| Seelos Therapeutics, Inc.
|
50
/ 100
| 0.053
| 60.3%
| -1,480.0%
| 171.8%
| €435.51K
|
| Altimmune, Inc.
|
50
/ 100
| -6.3
| -74,850.0%
| -452,310.0%
| -38.4%
| -€1.21M
|
| Jounce Therapeutics, Inc.
|
52
/ 100
| -2
| 100.0%
| -63.7%
| -24.0%
| -€307.55K
|
| Capricor Therapeutics, Inc.
|
50
/ 100
| -7.4
| -86.3%
| -778.8%
| -64.8%
| -€436.42K
|
| 4D pharma plc
|
50
/ 100
| 0
| 100.0%
| -27,014.7%
| -56.1%
| -€259.49K
|
| Berkeley Lights, Inc.
|
47
/ 100
| -0.87
| 69.4%
| -123.3%
| -33.3%
| -€298.92K
|
| G1 Therapeutics, Inc.
|
50
/ 100
| -8.5
| 89.4%
| -65.1%
| -45.4%
| -€381.28K
|
| Editas Medicine, Inc.
|
50
/ 100
| -0.85
| 97.0%
| -428.7%
| -99.1%
| -€691.82K
|
| Bio-Techne Corporation
|
53
/ 100
| 104
| 65.5%
| 9.3%
| 3.1%
| €21.42K
|
| Paratek Pharmaceuticals, Inc.
|
51
/ 100
| -1.9
| 84.9%
| -26.6%
| -46.0%
| -€213.30K
|
| CorMedix Inc.
|
49
/ 100
| 6.1
| 92.6%
| 48.5%
| 21.6%
| €2.16M
|
| Viridian Therapeutics, Inc.
|
50
/ 100
| -4.4
| 99.8%
| -463.5%
| -52.3%
| -€1.80M
|
| Nxera Pharma Co., Ltd.
|
50
/ 100
| -27
| 72.5%
| -17.5%
| -2.3%
| -€45.53K
|
| Legend Biotech Corporation
|
49
/ 100
| -14
| 59.9%
| -20.9%
| -14.0%
| -€78.66K
|
| Halozyme Therapeutics, Inc.
|
52
/ 100
| 11
| 84.5%
| 59.3%
| 26.8%
| €1.45M
|
| ALK-Abelló A/S
|
51
/ 100
| 38
| 65.9%
| 24.2%
| 13.0%
| €53.88K
|
| Equillium, Inc.
|
50
/ 100
| -0.57
| 97.8%
| -554.9%
| -70.8%
| -€594.13K
|
| CytomX Therapeutics, Inc.
|
49
/ 100
| 16
| 100.0%
| 20.5%
| 17.7%
| €200.52K
|
| Albireo Pharma, Inc.
|
50
/ 100
| -6.7
| 95.6%
| -214.2%
| -42.8%
| -€899.99K
|
| Spero Therapeutics, Inc.
|
54
/ 100
| -3.5
| 100.0%
| -155.6%
| -82.5%
| -€1.19M
|
| Relief Therapeutics Holding AG
|
50
/ 100
| -0.35
| 10.4%
| -249.6%
| -131.9%
| -€2.20M
|
| Emmaus Life Sciences, Inc.
|
50
/ 100
| -0.15
| 92.2%
| -10.2%
| -35.1%
| -€182.58K
|
| ABIVAX SA
|
50
/ 100
| -1.1
| 91.8%
| -3,281.1%
| -311.6%
| -€5.40M
|
| Oragenics, Inc.
|
50
/ 100
| -0.35
| 0.0%
| -303.6%
| -481.4%
| -€2.92M
|
| Champions Oncology, Inc.
|
46
/ 100
| 30
| 5.2%
| 8.8%
| 9.6%
| €11.85K
|
| Ocular Therapeutix, Inc.
|
50
/ 100
| -5.6
| 88.9%
| -450.2%
| -60.8%
| -€776.03K
|
| Selecta Biosciences, Inc.
|
50
/ 100
| -2
| 81.1%
| 122.8%
| -18.5%
| -€918.28K
|
| India Globalization Capital, Inc.
|
50
/ 100
| -3.8
| 46.2%
| -731.8%
| -66.2%
| -€81.94K
|
| Stoke Therapeutics, Inc.
|
46
/ 100
| 16
| 99.0%
| 13.2%
| 11.3%
| €269.91K
|
| BioMarin Pharmaceutical Inc.
|
57
/ 100
| 33
| 81.3%
| 20.0%
| 4.4%
| €93.77K
|
| Catalyst Pharmaceuticals, Inc.
|
56
/ 100
| 14
| 82.0%
| 44.8%
| 20.7%
| €1.02M
|
| Clinuvel Pharmaceuticals Limited
|
54
/ 100
| 10
| 76.8%
| 49.2%
| 26.4%
| €2.62M
|
| Clovis Oncology, Inc.
|
50
/ 100
| 0
| 65.6%
| -209.1%
| -72.6%
| -€519.45K
|
| Destiny Pharma plc
|
50
/ 100
| -0.0024
| 98.1%
| -1,487.4%
| -122.1%
| -€933.89K
|
| Viracta Therapeutics, Inc.
|
50
/ 100
| -0.017
| 55.4%
| -6,397.0%
| -197.1%
| -€1.42M
|
| Oxurion N.V.
|
50
/ 100
| -0.04
| -118.6%
| -11,780.2%
| -189.0%
| -€855.82K
|
| Genmab A/S
|
52
/ 100
| 10
| 94.8%
| 36.5%
| 19.5%
| €442.98K
|
| OSE Immunotherapeutics SA
|
50
/ 100
| 11
| 97.0%
| -8.9%
| 10.7%
| €174.95K
|
| Moderna, Inc.
|
58
/ 100
| -4
| 11.7%
| -156.3%
| -25.7%
| -€457.54K
|
| Avid Bioservices, Inc.
|
47
/ 100
| -5.3
| 7.7%
| -13.5%
| -47.0%
| -€349.04K
|
| XOMA Corporation
|
49
/ 100
| 16
| 94.9%
| 4.8%
| 7.3%
| €1.27M
|
| ERYTECH Pharma S.A.
|
50
/ 100
| -0.025
| -587.3%
| -1,605.3%
| -87.8%
| -€1.44M
|
| Novavax, Inc.
|
48
/ 100
| 3.4
| 91.9%
| 29.3%
| 29.0%
| €305.72K
|
| Harpoon Therapeutics, Inc.
|
50
/ 100
| -28
| 92.5%
| -104.8%
| -64.9%
| -€584.13K
|
| Northwest Biotherapeutics, Inc.
|
50
/ 100
| -4.2
| 78.7%
| -6,927.3%
| -295.3%
| -€3.08M
|
| AVEO Pharmaceuticals, Inc.
|
47
/ 100
| 0
| 87.4%
| -26.9%
| -40.0%
| -€302.72K
|
| Alterity Therapeutics Limited
|
50
/ 100
| -5.9
| 97.3%
| -392.7%
| -53.8%
| -€1.45M
|
| Geron Corporation
|
47
/ 100
| -12
| 86.2%
| -34.4%
| -14.1%
| -€297.48K
|
| Veracyte, Inc.
|
52
/ 100
| 72
| 67.2%
| 5.0%
| 2.2%
| €31.33K
|
| Nanobiotix S.A.
|
50
/ 100
| -2.4
| 106.0%
| -143.9%
| -188.4%
| -€788.11K
|
| Poxel S.A.
|
50
/ 100
| -0.61
| -460.0%
| -539.1%
| -1,079.9%
| -€10.06M
|
| Genocea Biosciences, Inc.
|
51
/ 100
| 0
| 100.0%
| -20,525.2%
| -101.2%
| -€451.89K
|
| Navidea Biopharmaceuticals, Inc.
|
50
/ 100
| -0.059
| -19,972.8%
| -1,668,791.0%
| -20.7%
| -€91.55K
|
| Akebia Therapeutics, Inc.
|
51
/ 100
| -59
| 78.8%
| 7.9%
| -4.4%
| -€74.84K
|
| Adaptive Biotechnologies Corporation
|
57
/ 100
| -20
| 71.8%
| -30.9%
| -16.2%
| -€109.53K
|
| Oxford BioDynamics Plc
|
50
/ 100
| -0.003
| -917.5%
| -1,613.7%
| -178.2%
| -€535.34K
|
| Barinthus Biotherapeutics plc
|
50
/ 100
| -0.51
| -9.5%
| 898.1%
| -69.5%
| -€615.36K
|
| Eiger BioPharmaceuticals, Inc.
|
50
/ 100
| -0.17
| 95.9%
| -455.1%
| -193.1%
| -€1.14M
|
| Novo Nordisk A/S
|
56
/ 100
| 22
| 82.0%
| 42.0%
| 20.3%
| €179.50K
|
| MedinCell S.A.
|
50
/ 100
| -9
| 113.6%
| -183.7%
| -98.3%
| -€441.75K
|
| Oncopeptides AB (publ)
|
48
/ 100
| -1.2
| 96.6%
| -512.4%
| -195.8%
| -€315.95K
|
| Genus plc
|
52
/ 100
| 0.48
| 100.0%
| 3.6%
| 3.0%
| €8.95K
|
| Outlook Therapeutics, Inc.
|
49
/ 100
| -1.8
| 70.8%
| -4,824.5%
| -194.0%
| -€1.61M
|
| Applied Therapeutics, Inc.
|
50
/ 100
| -2.9
| 78.6%
| -9,850.2%
| -52.8%
| -€441.35K
|
| BioRestorative Therapies, Inc.
|
50
/ 100
| -1.1
| 79.6%
| -3,785.1%
| -224.5%
| -€980.98K
|
| Crinetics Pharmaceuticals, Inc.
|
50
/ 100
| -7.2
| -5,855.9%
| -31,130.2%
| -35.4%
| -€824.55K
|
| Marinus Pharmaceuticals, Inc.
|
50
/ 100
| -0.22
| 88.9%
| -395.9%
| -220.8%
| -€725.14K
|
| Ardelyx, Inc.
|
50
/ 100
| -16
| 89.5%
| -9.5%
| -11.6%
| -€121.92K
|
| Orgenesis Inc.
|
50
/ 100
| -0.25
| 139.3%
| 724.9%
| -148.0%
| -€256.32K
|
| FibroGen, Inc.
|
52
/ 100
| 0.15
| 82.7%
| 105.0%
| 157.4%
| €816.27K
|
| Pulmatrix, Inc.
|
50
/ 100
| -4.9
| 100.0%
| -207,100.0%
| -124.8%
| -€2.65M
|
| Abivax S.A.
|
50
/ 100
| -1.4
| 72.2%
| -2,799.6%
| -238.0%
| -€4.13M
|
| Liquidia Corporation
|
45
/ 100
| -15
| 92.7%
| -155.0%
| -29.1%
| -€402.12K
|
| CTI BioPharma Corp.
|
50
/ 100
| -16
| 94.1%
| -71.2%
| -68.6%
| -€516.44K
|
| BioCryst Pharmaceuticals, Inc.
|
52
/ 100
| -254
| 97.4%
| 12.7%
| -2.0%
| -€12.89K
|
| TFF Pharmaceuticals, Inc.
|
50
/ 100
| -0.016
| 76.9%
| -1,068.2%
| -261.7%
| -€830.21K
|
| Heidelberg Pharma AG
|
50
/ 100
| -9.3
| 76.9%
| -640.2%
| -37.3%
| -€221.98K
|
| Bolt Biotherapeutics, Inc.
|
51
/ 100
| -6.2
| 94.4%
| -884.4%
| -65.6%
| -€699.02K
|
| Novan, Inc.
|
50
/ 100
| 2.6
| 65.8%
| -144.2%
| 1.3%
| €9.45K
|
| Pharma Mar, S.A.
|
50
/ 100
| 35
| 95.0%
| 16.6%
| 12.1%
| €84.02K
|
| IGM Biosciences, Inc.
|
48
/ 100
| -1.4
| 98.1%
| -19.2%
| -49.9%
| -€305.13K
|
| Mereo BioPharma Group plc
|
50
/ 100
| -10
| 73.4%
| -9,398.2%
| -77.6%
| -€983.48K
|
| BioInvent International AB (publ)
|
49
/ 100
| -7.5
| 98.6%
| -142.3%
| -41.2%
| -€259.71K
|
| Soligenix, Inc.
|
50
/ 100
| -0.84
| -11.1%
| -183,452.1%
| -128.6%
| -€450.64K
|
| Evolva Holding SA
|
50
/ 100
| -0.37
| 1,934.8%
| 4,630.8%
| -297.5%
| -€463.63K
|
| Sensorion SA
|
50
/ 100
| -2.3
| 91.3%
| -461.4%
| -70.6%
| -€821.52K
|
| Ocugen, Inc.
|
50
/ 100
| -5.3
| 100.0%
| -1,112.9%
| -111.2%
| -€573.92K
|
| Dianthus Therapeutics, Inc.
|
48
/ 100
| -4.6
| 96.8%
| -4,558.4%
| -21.9%
| -€1.38M
|
| Vertex Pharmaceuticals Incorporated
|
54
/ 100
| 32
| 86.3%
| 34.1%
| 14.8%
| €513.09K
|
| Zai Lab Limited
|
51
/ 100
| -23
| 61.4%
| -51.6%
| -17.8%
| -€94.24K
|
| Zealand Pharma A/S
|
50
/ 100
| 5.1
| 100.1%
| 78.8%
| 38.9%
| €2.32M
|
| Infinity Pharmaceuticals, Inc.
|
52
/ 100
| -0.018
| 39.7%
| -1,636.7%
| -188.0%
| -€1.13M
|
| Camurus AB (publ)
|
53
/ 100
| 46
| 93.2%
| 39.7%
| 16.9%
| €310.71K
|
| UCB SA
|
53
/ 100
| 17
| 70.1%
| 17.6%
| 9.1%
| €173.66K
|
| Gritstone bio, Inc.
|
50
/ 100
| -0.029
| -325.1%
| -8,786.8%
| -93.3%
| -€490.46K
|
| Takara Bio Inc.
|
50
/ 100
| 167
| 58.3%
| 4.6%
| 0.4%
| €1.70K
|
| Gubra A/S
|
50
/ 100
| 5
| 93.4%
| 75.1%
| 58.4%
| €875.45K
|
| Transgene SA
|
51
/ 100
| -2.2
| -702.2%
| -2,392.5%
| -145.6%
| -€414.53K
|
| Matinas BioPharma Holdings, Inc.
|
50
/ 100
| -0.3
| -12.9%
| -976.9%
| -180.3%
| -€4.96M
|
| GB Sciences, Inc.
|
50
/ 100
| -0.16
| 100.0%
| -872.7%
| -1,104.5%
| -€444.28K
|
| Adverum Biotechnologies, Inc.
|
48
/ 100
| -0.31
| 323.4%
| 4,419.3%
| -244.1%
| -€971.13K
|
| Agenus Inc.
|
47
/ 100
| -4
| 20.2%
| -56.6%
| -15.1%
| -€94.92K
|
| Adagene Inc.
|
51
/ 100
| -1.4
| -1,088.5%
| -58,950.5%
| -83.3%
| -€342.14K
|
| Krystal Biotech, Inc.
|
52
/ 100
| 20
| 68.8%
| 42.4%
| 16.0%
| €616.00K
|
| Vanda Pharmaceuticals Inc.
|
50
/ 100
| -3.2
| 0.3%
| -57.1%
| -14.0%
| -€194.86K
|
| EyePoint Pharmaceuticals, Inc.
|
50
/ 100
| -3
| 94.1%
| -515.7%
| -81.7%
| -€1.06M
|
| Cardiff Oncology, Inc.
|
51
/ 100
| -5.1
| 80.8%
| -10,719.6%
| -79.1%
| -€1.34M
|
| BRAIN Biotech AG
|
50
/ 100
| -3.8
| 56.6%
| -16.4%
| -16.1%
| -€39.51K
|
| Aravive, Inc.
|
50
/ 100
| -0.036
| -663.2%
| -372.7%
| -621.9%
| -€3.00M
|
| Alector, Inc.
|
50
/ 100
| -1.5
| 92.3%
| -179.1%
| -32.1%
| -€524.30K
|
| Valneva SE
|
49
/ 100
| -6.9
| 49.0%
| -25.6%
| -14.2%
| -€94.03K
|
| Quantum Genomics SA
|
50
/ 100
| -0.41
| -22,482.2%
| -38,080.2%
| -3,401.7%
| -€4.02M
|
| Oxford Biomedica plc
|
50
/ 100
| -0.02
| 41.1%
| -80.2%
| -82.8%
| -€242.70K
|
| Blueprint Medicines Corporation
|
47
/ 100
| -53
| 95.8%
| -31.0%
| -13.0%
| -€194.47K
|
| Adocia SA
|
50
/ 100
| -2.2
| -158.6%
| -158.0%
| -112.8%
| -€401.09K
|
| Lineage Cell Therapeutics, Inc.
|
50
/ 100
| -2.4
| 97.8%
| -325.3%
| -75.5%
| -€823.14K
|
| Aligos Therapeutics, Inc.
|
50
/ 100
| -0.54
| 64.9%
| -3,277.9%
| -78.8%
| -€1.05M
|
| Immutep Limited
|
50
/ 100
| -5.2
| -839.9%
| -2,208.1%
| -66.3%
| -€1.49M
|
| Kura Oncology, Inc.
|
50
/ 100
| -2.7
| 79.6%
| -230.5%
| -33.4%
| -€962.02K
|
| Sensei Biotherapeutics, Inc.
|
51
/ 100
| -0.34
| 0.0%
| 527.8%
| -87.5%
| -€1.47M
|
| Clearside Biomedical, Inc.
|
48
/ 100
| -2.4
| 85.6%
| -689.8%
| -223.3%
| -€691.85K
|
| Generex Biotechnology Corporation
|
50
/ 100
| 0
| 48.2%
| -4,952.5%
| -8.6%
| -€223.19K
|
| KalVista Pharmaceuticals, Inc.
|
51
/ 100
| -3.2
| 89.4%
| -1,343.0%
| -61.9%
| -€1.19M
|
| Syndax Pharmaceuticals, Inc.
|
54
/ 100
| -3
| 96.2%
| -275.1%
| -56.5%
| -€982.79K
|
| Oxford Nanopore Technologies plc
|
50
/ 100
| -0.043
| 55.4%
| -89.2%
| -39.7%
| -€222.13K
|
| WuXi Biologics (Cayman) Inc.
|
51
/ 100
| 106
| 40.8%
| 25.1%
| 11.3%
| €66.40K
|
| Reata Pharmaceuticals, Inc.
|
50
/ 100
| -82
| 96.5%
| -243.8%
| -15.9%
| -€212.40K
|
| Surface Oncology, Inc.
|
53
/ 100
| -0.69
| 100.0%
| -298.0%
| -142.4%
| -€2.29M
|
| Catalyst Biosciences, Inc.
|
55
/ 100
| 81
| 95.5%
| 11.2%
| 6.0%
| €13.96K
|
| Pharming Group N.V.
|
50
/ 100
| 2.4K
| 89.9%
| 7.3%
| 0.1%
| €805.27
|
| Provectus Biopharmaceuticals, Inc.
|
50
/ 100
| -5
| 20.2%
| -1,493.3%
| -1,595.7%
| -€951.04K
|
| Ultragenyx Pharmaceutical Inc.
|
50
/ 100
| -6.1
| 83.3%
| -86.3%
| -48.7%
| -€381.61K
|
| Verastem, Inc.
|
50
/ 100
| -1.4
| -247.6%
| -4,708.9%
| -136.3%
| -€2.63M
|
| Intellia Therapeutics, Inc.
|
53
/ 100
| -2
| -41.7%
| -832.2%
| -48.2%
| -€942.10K
|
| Rhythm Pharmaceuticals, Inc.
|
52
/ 100
| -21
| 89.4%
| -106.8%
| -37.9%
| -€578.77K
|
| PureTech Health plc
|
50
/ 100
| -15
| -321.7%
| -3,995.7%
| -5.7%
| -€297.73K
|
| Fate Therapeutics, Inc.
|
48
/ 100
| -1.1
| 54.1%
| -2,448.2%
| -45.4%
| -€734.46K
|
| Sorrento Therapeutics, Inc.
|
50
/ 100
| -0.0021
| 44.6%
| -720.9%
| -120.3%
| -€492.86K
|
| AnaptysBio, Inc.
|
46
/ 100
| -8.3
| 81.1%
| -16.9%
| -24.0%
| -€529.96K
|
| Enanta Pharmaceuticals, Inc.
|
50
/ 100
| -1.9
| 22.5%
| -149.4%
| -30.6%
| -€598.18K
|
| ImmunityBio, Inc.
|
50
/ 100
| -8.2
| 89.8%
| -315.8%
| 0.0%
| -€442.47K
|
| Sage Therapeutics, Inc.
|
50
/ 100
| -1.4
| 89.5%
| -461.3%
| -71.2%
| -€726.66K
|
| TG Therapeutics, Inc.
|
52
/ 100
| 101
| 87.0%
| 18.9%
| 8.6%
| €146.27K
|
| Innate Pharma S.A.
|
51
/ 100
| -2
| -82.6%
| -215.7%
| -86.2%
| -€442.56K
|
| GenSight Biologics S.A.
|
50
/ 100
| -0.65
| 35.7%
| -1,055.3%
| -373.9%
| -€2.51M
|
| REGENXBIO Inc.
|
48
/ 100
| -2.9
| 50.0%
| -96.0%
| -33.9%
| -€429.24K
|
| Ampio Pharmaceuticals, Inc.
|
50
/ 100
| -0.00036
| 100.0%
| -3,884.9%
| -150.5%
| -€1.23M
|
| BioLineRx Ltd.
|
50
/ 100
| -2.7
| 59.3%
| -84.1%
| -18.1%
| -€237.91K
|
| NRx Pharmaceuticals, Inc.
|
50
/ 100
| -1.6
| 59.8%
| -5,704.5%
| -253.8%
| -€16.21M
|
| Hansa Biopharma AB (publ)
|
50
/ 100
| -2.7
| 59.5%
| -302.2%
| -86.4%
| -€439.17K
|
| Bellerophon Therapeutics, Inc.
|
50
/ 100
| -0.013
| 99.9%
| -195.7%
| -234.4%
| -€552.15K
|
| Arix Bioscience plc
|
50
/ 100
| -0.018
| 38.1%
| 322.6%
| -42.3%
| -€13.01M
|
| Revolution Medicines, Inc.
|
43
/ 100
| -7.9
| 48.5%
| -396.4%
| -42.7%
| -€1.33M
|
| La Jolla Pharmaceutical Company
|
48
/ 100
| 0
| 80.9%
| -5.5%
| 1.5%
| €21.24K
|
| Ionis Pharmaceuticals, Inc.
|
49
/ 100
| -0.045
| 98.8%
| -28.8%
| -4,257.4%
| -€102.87M
|
| CymaBay Therapeutics, Inc.
|
50
/ 100
| -34
| 97.8%
| -327.2%
| -25.7%
| -€941.66K
|
| Abcam plc
|
50
/ 100
| 0
| 69.9%
| 12.8%
| 3.5%
| €19.69K
|
| Celyad Oncology SA
|
50
/ 100
| -1.2
| -82.2%
| -5,614.3%
| -249.8%
| -€837.12K
|
| Avacta Group Plc
|
49
/ 100
| -0.02
| 33.3%
| -151.6%
| -76.1%
| -€508.48K
|
| Addex Therapeutics Ltd
|
50
/ 100
| -1.6
| 100.0%
| -2,624.3%
| -71.1%
| -€3.26M
|
| Ocuphire Pharma, Inc.
|
50
/ 100
| -0.84
| 608.8%
| 1,501.0%
| -196.4%
| -€4.32M
|
| Atreca, Inc.
|
52
/ 100
| -0.038
| -2,420.2%
| -22,844.5%
| -360.9%
| -€899.69K
|
| Concert Pharmaceuticals, Inc.
|
51
/ 100
| 0
| 100.0%
| -121,474.9%
| -38.8%
| -€884.30K
|
| Genfit S.A.
|
49
/ 100
| -22
| 96.8%
| 4.1%
| -3.9%
| -€46.94K
|
| AnGes, Inc.
|
50
/ 100
| -0.9
| 36.6%
| -900.5%
| -494.2%
| -€2.80M
|
| ChromaDex Corporation
|
50
/ 100
| 54
| 133.7%
| 32.4%
| 20.8%
| €167.29K
|
| Karyopharm Therapeutics Inc.
|
51
/ 100
| -0.31
| 95.9%
| -73.1%
| -129.5%
| -€380.40K
|
| Laboratorios Farmaceuticos Rovi, S.A.
|
51
/ 100
| 14
| 65.2%
| 26.8%
| 23.2%
| €91.68K
|
| Adaptimmune Therapeutics plc
|
49
/ 100
| -0.41
| 94.8%
| -252.3%
| -129.9%
| -€285.71K
|
| Kuros Biosciences AG
|
45
/ 100
| -69
| 87.8%
| -0.5%
| -13.6%
| -€132.34K
|
| Heron Therapeutics, Inc.
|
50
/ 100
| -23
| 73.9%
| 1.0%
| -5.5%
| -€94.78K
|
| BioSenic S.A.
|
50
/ 100
| -0.044
| 88.5%
| -304.0%
| -317.1%
| -€2.48M
|
| KemPharm, Inc.
|
50
/ 100
| -32
| 73.8%
| -153.2%
| -6.0%
| -€574.28K
|
| Onconova Therapeutics, Inc.
|
50
/ 100
| -0.000000062
| -51,242.7%
| -62,233.8%
| -1,338,153.0%
| -€8.86T
|
| Armata Pharmaceuticals, Inc.
|
51
/ 100
| -1.6
| 75.5%
| -730.9%
| -52.4%
| -€665.72K
|
| Sangamo Therapeutics, Inc.
|
50
/ 100
| -1.1
| 100.0%
| -331.6%
| -122.9%
| -€506.84K
|
| X4 Pharmaceuticals, Inc.
|
50
/ 100
| -0.2
| 83.2%
| -291.1%
| -58.1%
| -€566.34K
|
| AgeX Therapeutics, Inc.
|
50
/ 100
| -7.1
| -50.6%
| -33,703.8%
| -70.0%
| -€1.85M
|
| Cytokinetics, Incorporated
|
50
/ 100
| -5.3
| -127.5%
| -656.9%
| -52.3%
| -€1.29M
|
| Immunocore Holdings plc
|
47
/ 100
| -63
| 99.3%
| -11.9%
| -2.6%
| -€48.82K
|
| Omeros Corporation
|
49
/ 100
| -1.8
| -48.5%
| -31,401.7%
| -65.2%
| -€510.81K
|
| Deinove SA
|
50
/ 100
| -0.095
| -4,758.2%
| -8,616.9%
| -114.7%
| -€270.81K
|
| Precision BioSciences, Inc.
|
49
/ 100
| -0.68
| -1.6%
| -12,980.9%
| -89.4%
| -€659.25K
|
| Idorsia Ltd
|
50
/ 100
| -3.2
| 65.7%
| -48.5%
| -26.8%
| -€225.86K
|
| Silence Therapeutics plc
|
51
/ 100
| -0.24
| 35.0%
| -379.8%
| -10.7%
| -€98.60K
|
| Larimar Therapeutics, Inc.
|
50
/ 100
| -1.5
| 63.9%
| -57,996.7%
| -70.5%
| -€1.73M
|
| IXICO plc
|
48
/ 100
| -0.033
| 46.2%
| -34.9%
| -24.2%
| -€48.52K
|
| ImmunoGen, Inc.
|
50
/ 100
| -120
| 98.7%
| -27.9%
| -8.9%
| -€224.67K
|
| argenx SE
|
58
/ 100
| 40
| 92.7%
| 2.1%
| 12.5%
| €476.63K
|
| PhaseBio Pharmaceuticals, Inc.
|
50
/ 100
| 0
| 100.0%
| 3,588.2%
| 125.6%
| €395.10K
|
| Acer Therapeutics Inc.
|
50
/ 100
| 0
| 77.5%
| -7,376.2%
| -346.3%
| -€1.38M
|
| Polyphor AG
|
50
/ 100
| 0
| 100.0%
| -1,688.1%
| -50.4%
| -€1.20M
|
| Oramed Pharmaceuticals Inc.
|
50
/ 100
| -3.8
| -2.4%
| -683.7%
| -14.9%
| -€1.58M
|
| Cara Therapeutics, Inc.
|
50
/ 100
| -12
| 61.0%
| -308.2%
| -47.8%
| -€1.78M
|
| Starpharma Holdings Limited
|
50
/ 100
| -3.5
| -0.4%
| -277.0%
| -62.4%
| -€231.76K
|
| ReNeuron Group plc
|
50
/ 100
| -0.000036
| -299.6%
| -1,509.0%
| -197.8%
| -€562.86K
|
| Amicus Therapeutics, Inc.
|
52
/ 100
| 95
| 90.5%
| 4.5%
| 2.3%
| €33.92K
|
| Rigel Pharmaceuticals, Inc.
|
49
/ 100
| 3.4
| 93.1%
| 42.2%
| 46.7%
| €595.62K
|
| Pieris Pharmaceuticals, Inc.
|
50
/ 100
| -0.51
| -1,260.4%
| -23,801.9%
| -52.4%
| -€649.21K
|
| Alpine Immune Sciences, Inc.
|
50
/ 100
| -121
| 59.5%
| -90.9%
| -9.9%
| -€220.92K
|
| Mirati Therapeutics, Inc.
|
50
/ 100
| -5.7
| -283.5%
| -2,002.7%
| -64.3%
| -€1.05M
|
| BB Biotech AG
|
50
/ 100
| -3.9
| 99.3%
| 115.0%
| -23.8%
| -€47.29M
|
| Verrica Pharmaceuticals Inc.
|
52
/ 100
| -2.1
| 91.9%
| -53.2%
| -63.6%
| -€312.04K
|
| Ascendis Pharma A/S
|
50
/ 100
| -33
| 86.8%
| -22.5%
| -20.2%
| -€229.05K
|
| Chimerix, Inc.
|
48
/ 100
| -9.1
| 100.0%
| -45,550.5%
| -60.5%
| -€952.84K
|
| Coherus BioSciences, Inc.
|
47
/ 100
| 0.6
| 45.3%
| -212.4%
| 30.0%
| €578.86K
|
| scPharmaceuticals Inc.
|
50
/ 100
| -2.4
| 68.5%
| -133.2%
| -114.3%
| -€482.16K
|
| NGM Biopharmaceuticals, Inc.
|
51
/ 100
| -0.92
| 26.3%
| -3,429.1%
| -82.8%
| -€862.92K
|
| Carisma Therapeutics, Inc.
|
50
/ 100
| 3.1
| 86.1%
| 146.9%
| 122.7%
| €148.89K
|
| Verona Pharma plc
|
57
/ 100
| -95
| 95.2%
| -25.3%
| -14.2%
| -€330.82K
|
| Amarin Corporation plc
|
51
/ 100
| -64
| 44.2%
| -45.5%
| -13.1%
| -€266.93K
|
| Nicox S.A.
|
50
/ 100
| -0.87
| 24.6%
| 124.0%
| -25.7%
| -€567.03K
|
| Centessa Pharmaceuticals plc
|
47
/ 100
| -6.9
| 97.4%
| -1,425.3%
| -54.1%
| -€2.68M
|
| Homology Medicines, Inc.
|
50
/ 100
| -0.8
| -0.4%
| 2,808.2%
| -44.9%
| -€3.15M
|
| Genprex, Inc.
|
50
/ 100
| -0.5
| 0.0%
| -134,539.7%
| -451.6%
| -€981.43K
|
| Inventiva S.A.
|
50
/ 100
| -0.98
| 92.2%
| -565.7%
| -232.6%
| -€3.64M
|
| Alnylam Pharmaceuticals, Inc.
|
74
/ 100
| 897
| 84.0%
| 8.2%
| 0.9%
| €16.64K
|
| Cartesian Therapeutics, Inc.
|
50
/ 100
| -5.7
| -1,073.0%
| -8,386.5%
| -12.9%
| -€619.11K
|
| Santhera Pharmaceuticals Holding AG
|
50
/ 100
| -61
| 69.3%
| 1.3%
| -2.1%
| -€37.15K
|
| Marker Therapeutics, Inc.
|
50
/ 100
| -1.5
| -54.9%
| -280.8%
| -98.9%
| -€2.49M
|
| Savara Inc.
|
50
/ 100
| -3.3
| 22.8%
| -44,597.1%
| -82.1%
| -€1.67M
|
| Codexis, Inc.
|
49
/ 100
| -3.1
| 79.3%
| -112.7%
| -51.6%
| -€289.70K
|
| BioNTech SE
|
66
/ 100
| -39
| 82.5%
| -29.6%
| -2.7%
| -€84.41K
|
| Provention Bio, Inc.
|
50
/ 100
| -21
| 96.0%
| -993.9%
| -47.7%
| -€552.95K
|
| ObsEva SA
|
50
/ 100
| 1.8
| 54.1%
| 3.4%
| 87.8%
| €449.78K
|
| Nektar Therapeutics
|
51
/ 100
| -0.98
| 86.9%
| -156.7%
| -40.1%
| -€1.69M
|
| IDEAYA Biosciences, Inc.
|
49
/ 100
| -12
| 3.0%
| -97.2%
| -13.5%
| -€1.04M
|
| United Therapeutics Corporation
|
61
/ 100
| 9.8
| 88.6%
| 47.7%
| 17.3%
| €829.91K
|
| Spectrum Pharmaceuticals, Inc.
|
48
/ 100
| -3.3
| 88.7%
| -246.4%
| -60.4%
| -€644.24K
|
| Ovid Therapeutics Inc.
|
52
/ 100
| -0.63
| 98.2%
| -618.3%
| -56.9%
| -€1.35M
|
| Fortress Biotech, Inc.
|
50
/ 100
| 16
| 71.6%
| -143.6%
| 2.2%
| €33.62K
|
| IntelGenx Technologies Corp.
|
50
/ 100
| -2.7
| -83.1%
| -998.7%
| -168.4%
| -€195.70K
|
| BioXcel Therapeutics, Inc.
|
50
/ 100
| -0.16
| -46.3%
| -7,106.6%
| -152.3%
| -€1.57M
|
| Roquefort Therapeutics plc
|
52
/ 100
| -0.0085
| 86.2%
| -551.0%
| -47.2%
| -€447.01K
|
| Corcept Therapeutics Incorporated
|
63
/ 100
| 72
| 98.2%
| 8.8%
| 12.8%
| €179.16K
|
| Scorpius Holdings, Inc.
|
50
/ 100
| -0.000000043
| 39.0%
| -633.1%
| -268.1%
| -€547.20B
|
| Sarepta Therapeutics, Inc.
|
54
/ 100
| -14
| 21.4%
| -5.2%
| -7.8%
| -€168.54K
|
| PTC Therapeutics, Inc.
|
52
/ 100
| 5.4
| 90.8%
| 43.6%
| 28.4%
| €681.79K
|
| Basilea Pharmaceutica AG
|
48
/ 100
| 9.8
| 60.9%
| 16.7%
| 25.8%
| €421.35K
|
| Agios Pharmaceuticals, Inc.
|
49
/ 100
| -5
| 84.4%
| -1,061.8%
| -29.0%
| -€703.16K
|
| Plus Therapeutics, Inc.
|
49
/ 100
| -0.53
| 89.1%
| -366.4%
| -110.2%
| -€834.45K
|
| Cellectis S.A.
|
49
/ 100
| -3.6
| 91.0%
| -35.1%
| -10.3%
| -€139.39K
|
| Precigen, Inc.
|
48
/ 100
| -1.8
| 25.3%
| -1,798.2%
| -144.1%
| -€1.47M
|
| BeiGene, Ltd.
|
56
/ 100
| 382
| 86.2%
| 3.7%
| 0.9%
| €5.51K
|
| E-therapeutics Plc
|
50
/ 100
| -0.029
| 65.8%
| -3,030.6%
| -77.9%
| -€658.64K
|
| Humanigen, Inc.
|
50
/ 100
| 0
| 100.0%
| -3,061.2%
| -1,041.9%
| -€7.57M
|
| Immuron Limited
|
50
/ 100
| -1.4
| 66.0%
| -91.7%
| -113.0%
| -€955.78K
|
